The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of dual checkpoint-blockade with PSB205, an anti-PD-1/CTLA4 monoclonal antibody combination, manufactured and dispensed as a single product: A phase 1 study.
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; Epizyme; Ipsen
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals; Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Medivation (Inst); Mundipharma (Inst); Novartis (Inst); Plexxikon (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Expert Testimony - DOPF, PC; Meyers Law (Inst)
 
Judy S. Wang
Consulting or Advisory Role - BioNTech; Janssen Research & Development; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Aevi Genomic Medicine (Inst); Agenus (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bayer Health (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biosplice (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immune-Onc Therapeutics (Inst); Immunogen (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Klus Pharma (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); StingThera (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Breelyn A. Wilky
Consulting or Advisory Role - Adaptimmune; Adcendo; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Agenus; Exelixis
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Paul Algate
Employment - Sound Biologics
Leadership - Sound Biologics
Stock and Other Ownership Interests - Sound Biologics
 
Leah Plato
Research Funding - Sound Biologics (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Borys Korchin
Employment - ICON Clinical Research
Consulting or Advisory Role - ICON Clinical Research
 
Jelle W. Kylstra
Employment - Sound Biologics
Leadership - Sound Biologics
Stock and Other Ownership Interests - Sound Biologics
Research Funding - Sound Biologics